Novavax’s R&D Shift and Sanofi Partnership Could Be a Game Changer for NVAX

Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...

Shah Capital pushes for Novavax sale, warns of proxy fight

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is ...

Milestones Over Sales: The Sanofi Partnership Now Drives Novavax's Outlook

Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...

Shares of vaccine makers drop after FDA memo flags reports of child deaths

Shares in major COVID-19 vaccine makers fell on Monday after an internal U.S. Food and Drug Administration (FDA) memo reportedly suggested that vaccinations may have contributed to several child ...

Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast

Novavax, Inc. (NASDAQ: NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM ESTCompany ParticipantsRuxandra Draghia-Akli - Executive VP ...
Forbes

Novavax Shares Surge Over 130% After $1.4 Billion Covid Shot Deal With Sanofi

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot ...
Yahoo

Novavax's updated COVID vaccine is here. What to know about the shot.

On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory ...